C-Abl phosphorylates α-synuclein and regulates its degradation: Implication for α-synuclein clearance and contribution to the pathogenesis of parkinson's disease

Human Molecular Genetics

Volumn 23, Issue 11, 2014, Pages 2858-2879

  Mahul Mellier, Anne Laure ^a   Fauvet, Bruno ^a   Gysbers, Amanda ^b   Dikiy, Igor ^c   Oueslati, Abid ^a   Georgeon, Sandrine ^a   Lamontanara, Allan J ^a   Bisquertt, Alejandro ^d   Eliezer, David ^c   Masliah, Eliezer ^d   Halliday, Glenda ^b   Hantschel, Oliver ^a   Lashuel, Hilal A ^a  

^a EPFL   (Switzerland)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; ALPHA SYNUCLEIN; NILOTINIB;

ANIMAL CELL; ARTICLE; AUTOPHAGY; BRAIN TISSUE; CONTROLLED STUDY; ENZYMATIC ASSAY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MASS SPECTROMETRY; MESENCEPHALON; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; AGED; ANIMAL; BRAIN; C57BL MOUSE; ENZYMOLOGY; FEMALE; GENETICS; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PHOSPHORYLATION; TRANSGENIC MOUSE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; ANIMALS; BRAIN; FEMALE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MIDDLE AGED; PARKINSON DISEASE; PHOSPHORYLATION; PROTEOLYSIS; PROTO-ONCOGENE PROTEINS C-ABL;

EID: 84899894003     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddt674     Document Type: Article

References (77)

1. Moresco, E.M. and Koleske, A.J. (2003) Regulation of neuronal morphogenesis and synaptic function by Abl family kinases. Curr. Opin. Neurobiol., 13, 535-544.
2. Zukerberg, L.R., Patrick, G.N., Nikolic, M., Humbert, S., Wu, C.L., Lanier, L.M., Gertler, F.B., Vidal, M., Van Etten, R.A. and Tsai, L.H. (2000) Cables links Cdk5 and c-Abl and facilitates Cdk5 tyrosine phosphorylation, kinase upregulation, and neurite outgrowth. Neuron, 26, 633-646.
3. Jones, S.B., Lu, H.Y. and Lu, Q. (2004) Abl tyrosine kinase promotes dendrogenesis by inducing actin cytoskeletal rearrangements in cooperation with Rho family small GTPases in hippocampal neurons. J. Neurosci., 24, 8510-8521.
4. Woodring, P.J., Litwack, E.D., O'Leary, D.D., Lucero, G.R., Wang, J.Y. and Hunter, T. (2002) Modulation of the F-actin cytoskeleton by c-Abl tyrosine kinase in cell spreading and neurite extension. J. Cell Biol., 156, 879-892.
5. Lanier, L.M. and Gertler, F.B. (2000) From Abl to actin: Abl tyrosine kinase and associated proteins in growth cone motility. Curr. Opin. Neurobiol., 10, 80-87.
6. Koleske, A.J., Gifford, A.M., Scott, M.L., Nee, M., Bronson, R.T., Miczek, K.A. and Baltimore, D. (1998) Essential roles for the Abl and Arg tyrosine kinases in neurulation. Neuron, 21, 1259-1272.
7. Moresco, E.M., Scheetz, A.J., Bornmann, W.G., Koleske, A.J. and Fitzsimonds, R.M. (2003) Abl family nonreceptor tyrosine kinases modulate short-term synaptic plasticity. J. Neurophysiol., 89, 1678-1687.
8. Schlatterer, S.D., Acker, C.M. and Davies, P. (2011) c-Abl in neurodegenerative disease. J. Mol. Neurosci., 45, 445-452.
9. Cancino, G.I., Toledo, E.M., Leal, N.R., Hernandez, D.E., Yevenes, L.F., Inestrosa, N.C. and Alvarez, A.R. (2008) STI571 prevents apoptosis, tau phosphorylation and behavioural impairments induced by Alzheimer's beta-amyloid deposits. Brain J. Neurol., 131, 2425-2442.
10. Jing, Z., Caltagarone, J. and Bowser, R. (2009) Altered subcellular distribution of c-Abl in Alzheimer's disease. J. Alzheimer's Dis., 17, 409-422.
11. Tremblay, M.A., Acker, C.M. and Davies, P. (2010) Tau phosphorylated at tyrosine 394 is found in Alzheimer's disease tangles and can be a product of the Abl-related kinase, Arg. J. Alzheimer's Dis., 19, 721-733.
12. Ko, H.S., Lee, Y., Shin, J.H., Karuppagounder, S.S., Gadad, B.S., Koleske, A.J., Pletnikova, O., Troncoso, J.C., Dawson, V.L. and Dawson, T.M. (2010) Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function. Proc. Natl Acad. Sci. USA, 107, 16691-16696.
13. Imam, S.Z., Zhou, Q., Yamamoto, A., Valente, A.J., Ali, S.F., Bains, M., Roberts, J.L., Kahle, P.J., Clark, R.A. and Li, S. (2011) Novel regulation of parkin function through c-Abl-mediated tyrosine phosphorylation: implications for Parkinson's disease. J. Neurosci., 31, 157-163.
14. Alvarez, A.R., Klein, A., Castro, J., Cancino, G.I., Amigo, J., Mosqueira, M., Vargas, L.M., Yevenes, L.F., Bronfman, F.C. and Zanlungo, S. (2008) Imatinib therapy blocks cerebellar apoptosis and improves neurological symptoms in a mouse model of Niemann-Pick type C disease. FASEB J., 22, 3617-3627.
15. Estrada, L.D., Zanlungo, S.M. and Alvarez, A.R. (2011) C-Abl tyrosine kinase signaling: a new player inADtau pathology. Curr. Alzheimer Res., 8, 643-651.
16. Hantschel, O. and Superti-Furga, G. (2004) Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat. Rev. Mol. Cell Biol., 5, 33-44.
17. Sirvent, A., Benistant, C. and Roche, S. (2012) Oncogenic signaling by tyrosine kinases of the SRC family in advanced colorectal cancer. Am. J. Cancer Res., 2, 357-371.
18. Sun, X., Wu, F., Datta, R., Kharbanda, S. and Kufe, D. (2000) Interaction between protein kinase C delta and the c-Abl tyrosine kinase in the cellular response to oxidative stress. J. Biol. Chem., 275, 7470-7473.
19. Stuart, J.R., Kawai, H., Tsai, K.K., Chuang, E.Y. and Yuan, Z.M. (2005) c-Abl regulates early growth response protein (EGR1) in response to oxidative stress. Oncogene, 24, 8085-8092.
20. Yuan, Z.M., Shioya, H., Ishiko, T., Sun, X., Gu, J., Huang, Y.Y., Lu, H., Kharbanda, S., Weichselbaum, R. and Kufe, D. (1999) p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature, 399, 814-817.
21. Yoshida, K. (2007) Regulation for nuclear targeting of the Abl tyrosine kinase in response to DNA damage. Adv. Exp. Med. Biol., 604, 155-165.
22. Zhu, J. and Wang, J.Y. (2004) Death by Abl: a matter of location. Curr. Top. Dev. Biol., 59, 165-192.
23. Colicelli, J. (2010) ABL tyrosine kinases: evolution of function, regulation, and specificity. Sci. Signal., 3, re6.
24. Gonfloni, S., Maiani, E., Di Bartolomeo, C., Diederich, M. and Cesareni, G. (2012) Oxidative stress,DNAdamage, and c-Abl signaling: at the crossroad in neurodegenerative diseases? Int. J. Biochem. Cell Biol., 2012, 683097.
25. Alvarez, A.R., Sandoval, P.C., Leal, N.R., Castro, P.U. and Kosik, K.S. (2004) Activation of the neuronal c-Abl tyrosine kinase by amyloid-beta-peptide and reactive oxygen species. Neurobiol. Dis., 17, 326-336.
26. Hebron, M.L., Lonskaya, I. and Moussa, C.E. (2013) Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of alpha-synuclein in Parkinson's disease models. Hum. Mol. Genet., 22, 3315-3328.
27. Lin, Y.L., Meng, Y., Jiang, W.and Roux, B. (2013) Explaining why Gleevec is a specific and potent inhibitor of Abl kinase. Proc. Natl Acad. Sci. USA, 110, 1664-1669.
28. Deremer, D.L., Ustun, C. and Natarajan, K. (2008) Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clin. Therap., 30, 1956-1975.
29. Imam, S.Z., Trickler, W., Kimura, S., Binienda, Z.K., Paule, M.G., Slikker, W. Jr, Li, S., Clark, R.A. and Ali, S.F. (2013) Neuroprotective efficacy of a new brain-penetrating C-Abl inhibitor in a murine Parkinson's disease model. PLoS One, 8, e65129.
30. Lashuel, H.A., Overk, C.R., Oueslati, A. and Masliah, E. (2013) The many faces of alpha-synuclein: from structure and toxicity to therapeutic target. Nat. Rev. Neurosci., 14, 38-48.
31. Spillantini, M.G., Crowther, R.A., Jakes, R., Hasegawa, M. and Goedert, M. (1998) alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc. Natl Acad. Sci. USA, 95, 6469-6473.
32. Spillantini, M.G., Schmidt, M.L., Lee, V.M., Trojanowski, J.Q., Jakes, R. and Goedert, M. (1997) Alpha-synuclein in Lewy bodies. Nature, 388, 839-840.
33. Goedert, M. (2001) Alpha-synuclein and neurodegenerative diseases. Nat. Rev. Neurosci., 2, 492-501.
34. Polymeropoulos, M.H., Lavedan, C., Leroy, E., Ide, S.E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R. et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science (New York, NY), 276, 2045-2047.
35. Kruger, R., Kuhn, W., Muller, T., Woitalla, D., Graeber, M., Kosel, S., Przuntek, H., Epplen, J.T., Schols, L. and Riess, O. (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet., 18, 106-108.
36. Zarranz, J.J., Alegre, J., Gomez-Esteban, J.C., Lezcano, E., Ros, R., Ampuero, I., Vidal, L., Hoenicka, J., Rodriguez, O., Atares, B. et al. (2004) The new mutation, E46 K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol., 55, 164-173.
37. Choi, W., Zibaee, S., Jakes, R., Serpell, L.C., Davletov, B., Crowther, R.A. and Goedert, M. (2004) Mutation E46K increases phospholipid binding and assembly into filaments of human alpha-synuclein. FEBS Lett., 576, 363-368.
38. Gibb, W.R. and Lees, A.J. (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J. Neurol. Neurosurg. Psych., 51, 745-752.
39. Appel-Cresswell, S., Vilarino-Guell, C., Encarnacion, M., Sherman, H., Yu, I., Shah, B., Weir, D., Thompson, C., Szu-Tu, C., Trinh, J. et al. (2013) Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease. Mov. Disord., 28, 811-813.
40. Fleming, S.M., Salcedo, J., Fernagut, P.O., Rockenstein, E., Masliah, E., Levine, M.S. and Chesselet, M.F. (2004) Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. J. Neurosci., 24, 9434-9440.
41. Proukakis, C., Dudzik, C.G., Brier, T., MacKay, D.S., Cooper, J.M., Millhauser, G.L., Houlden, H. and Schapira, A.H. (2013) A novel alpha-synuclein missense mutation in Parkinson disease. Neurology, 80, 1062-1064.
42. Lesage, S., Anheim, M., Letournel, F., Bousset, L., Honoré, A., Rozas, N., Pieri, L., Madiona, K., Durr, A., Melki, R. et al. (2013) G51D a-synuclein mutation causes a novel Parkinsonian-pyramidal syndrome. Annals of neurology, 73, 459-471.
43. Hebron, M.L., Lonskaya, I. and Moussa, C.E. (2013) Tyrosine kinase inhibition facilitates autophagic SNCA/alpha-synuclein clearance. Autophagy, 9, 1249-1250.
44. Hantschel, O., Grebien, F. and Superti-Furga, G. (2012) The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL. Cancer Res., 72, 4890-4895.
45. Yang, J., Campobasso, N., Biju, M.P., Fisher, K., Pan, X.Q., Cottom, J., Galbraith, S., Ho, T., Zhang, H., Hong, X. et al. (2011) Discovery and characterization of a cell-permeable, small-molecule c-Abl kinase activator that binds to the myristoyl binding site. Chem. Biol., 18, 177-186.
46. Ellis, C.E., Schwartzberg, P.L., Grider, T.L., Fink, D.W. and Nussbaum, R.L. (2001) alpha-Synuclein is phosphorylated by membersof the Src family of protein-tyrosine kinases. J. Biol. Chem., 276, 3879-3884.
47. Nakamura, T., Yamashita, H., Takahashi, T. and Nakamura, S. (2001) Activated Fyn phosphorylates alpha-synuclein at tyrosine residue 125. Biochem. Biophys. Res. Commun., 280, 1085-1092.
48. Negro, A., Brunati, A.M., Donella-Deana, A., Massimino, M.L. and Pinna, L.A. (2002) Multiple phosphorylation of alpha-synuclein by protein tyrosine kinase Syk prevents eosin-induced aggregation. FASEB J., 16, 210-212.
49. Rockenstein, E., Mallory, M., Hashimoto, M., Song, D., Shults, C.W., Lang, I. and Masliah, E. (2002) Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J. Neurosci. Res., 68, 568-578.
50. Feller, S.M., Knudsen,B. and Hanafusa, H. (1994) c-Abl kinase regulates the protein binding activity of c-Crk. EMBO J., 13, 2341-2351.
51. Bertoncini, C.W., Jung, Y.S., Fernandez, C.O., Hoyer, W., Griesinger, C., Jovin, T.M. and Zweckstetter, M. (2005) Release of long-range tertiary interactions potentiates aggregation of natively unstructured alpha-synuclein. Proc. Natl Acad. Sci. USA, 102, 1430-1435.
52. Lue, L.F., Walker, D.G., Adler, C.H., Shill, H., Tran, H., Akiyama, H., Sue, L.I., Caviness, J., Sabbagh, M.N. and Beach, T.G. (2012) Biochemical increase in phosphorylated alpha-synuclein precedes histopathology of Lewy-type synucleinopathies. Brain Pathol. (Zurich, Switzerland), 22, 745-756.
53. Walker, D.G., Lue, L.F., Adler, C.H., Shill, H.A., Caviness, J.N., Sabbagh, M.N., Akiyama, H., Serrano, G.E., Sue, L.I. and Beach, T.G. (2013) Changes in properties of serine 129 phosphorylated alpha-synuclein with progression of Lewy-type histopathology in human brains. Exp. Neurol., 240, 190-204.
54. Masliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A. and Mucke, L. (2000) Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science (New York, NY), 287, 1265-1269.
55. Games, D., Seubert, P., Rockenstein, E., Patrick, C., Trejo, M., Ubhi, K., Ettle, B., Ghassemiam, M., Barbour, R., Schenk, D. et al. (2013)Axonopathy in an alpha-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated alpha-synuclein. Am. J. Pathol., 182, 940-953.
56. Masliah, E., Rockenstein, E., Veinbergs, I., Sagara, Y., Mallory, M., Hashimoto, M. and Mucke, L. (2001) beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc. Natl Acad. Sci. USA, 98, 12245-12250.
57. Rockenstein, E., Crews, L. and Masliah, E. (2007) Transgenic animal models of neurodegenerative diseases and their application to treatment development. Adv. Drug Deliv. Rev., 59, 1093-1102.
58. Oueslati, A., Schneider, B.L., Aebischer, P. and Lashuel, H.A. (2013) Pololike kinase 2 regulates selective autophagic alpha-synuclein clearance and suppresses its toxicity in vivo. Proceedings of the National Academy of Sciences of the United States of America, 110, E3945-3954.
59. Oueslati, A., Paleologou, K.E., Schneider, B.L., Aebischer, P. and Lashuel, H.A. (2012) Mimicking phosphorylation at serine 87 inhibits the aggregation of human alpha-synuclein and protects against its toxicity in a rat model of Parkinson's disease. J. Neurosci., 32, 1536-1544.
60. Hantschel, O., Rix, U. and Superti-Furga, G. (2008) Target spectrum of the BCR-ABLinhibitors imatinib, nilotinib and dasatinib. Leuk. Lymphoma, 49, 615-619.
61. Adrian, F.J., Ding, Q., Sim, T., Velentza, A., Sloan, C., Liu, Y., Zhang, G., Hur, W., Ding, S., Manley, P. et al. (2006) Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat. Chem. Biol., 2, 95-102.
62. Machiya, Y., Hara, S., Arawaka, S., Fukushima, S., Sato, H., Sakamoto, M., Koyama, S. and Kato, T. (2010) Phosphorylated alpha-synuclein at Ser-129 is targeted to the proteasome pathway in a ubiquitin-independent manner. J. Biol. Chem., 285, 40732-40744.
63. Ertmer, A., Huber, V., Gilch, S., Yoshimori, T., Erfle, V., Duyster, J., Elsasser, H.P. and Schatzl, H.M. (2007) The anticancer drug imatinib induces cellular autophagy. Leukemia, 21, 936-942.
64. Netzer, W.J., Dou, F., Cai, D., Veach, D., Jean, S., Li, Y., Bornmann, W.G., Clarkson, B., Xu, H. and Greengard, P. (2003) Gleevec inhibits beta-amyloid production but not Notch cleavage. Proc. Natl Acad. Sci. USA, 100, 12444-12449.
65. Seeliger, M.A., Young, M., Henderson, M.N., Pellicena, P., King, D.S., Falick, A.M. and Kuriyan, J. (2005) High yield bacterial expression of active c-Abl and c-Src tyrosine kinases. Protein Sci., 14, 3135-3139.
66. Hantschel, O., Warsch, W., Eckelhart, E., Kaupe, I., Grebien, F., Wagner, K.U., Superti-Furga, G. and Sexl, V. (2012) BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia. Nat. Chem. Biol., 8, 285-293.
67. Fauvet, B., Mbefo, M.K., Fares, M.B., Desobry, C., Michael, S., Ardah, M.T., Tsika, E., Coune, P., Prudent, M., Lion, N. et al. (2012) alpha-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. J. Biol. Chem., 287, 15345-15364.
68. Eliezer, D., Kutluay, E., Bussell, R. Jr. and Browne, G. (2001) Conformational properties of alpha-synuclein in its free and lipid-associated states. J. Mol. Biol., 307, 1061-1073.
69. Fauvet, B., Fares, M.B., Samuel, F., Dikiy, I., Tandon, A., Eliezer, D. and Lashuel, H.A. (2012) Characterization of semisynthetic and naturally Nalpha-acetylated alpha-synuclein in vitro and in intact cells: implications for aggregation and cellular properties of alpha-synuclein. J. Biol. Chem., 287, 28243-28262.
70. Delaglio, F., Grzesiek, S., Vuister, G.W., Zhu, G., Pfeifer, J. and Bax, A. (1995) NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J. Biomol. NMR, 6, 277-293.
71. Johnson, B.A., Stevens, S.P. and Williamson, J.M. (1994) Determination of the three-dimensional structure of margatoxin by 1H, 13C, 15N triple-resonance nuclear magnetic resonance spectroscopy. Biochemistry, 33, 15061-15070.
72. Azeredo da Silveira, S., Schneider, B.L., Cifuentes-Diaz, C., Sage, D., Abbas-Terki, T., Iwatsubo, T., Unser, M. and Aebischer, P. (2009) Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease. Hum. Mol. Gen., 18, 872-887.
73. Steiner, P., Sarria, J.C., Glauser, L., Magnin, S., Catsicas, S. and Hirling, H. (2002) Modulation of receptor cycling by neuron-enriched endosomal protein of 21 kD. J. Cell Biol., 157, 1197-1209.
74. Barde, I., Salmon, P. and Trono, D. (2010) Production and titration of lentiviral vectors. Curr. Prot. Neurosci. Chapter 4, Unit 4, p. 21.
75. Wigler, M., Silverstein, S., Lee, L.S., Pellicer, A., Cheng, Y. and Axel, R. (1977) Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells. Cell, 11, 223-232.
76. Abeliovich, A., Schmitz, Y., Farinas, I., Choi-Lundberg, D., Ho, W.H., Castillo, P.E., Shinsky, N., Verdugo, J.M., Armanini, M., Ryan, A. et al. (2000) Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron, 25, 239-252.
77. Paleologou, K.E., Oueslati, A., Shakked, G., Rospigliosi, C.C., Kim, H.Y., Lamberto, G.R., Fernandez, C.O., Schmid, A., Chegini, F., Gai, W.P. et al. (2010) Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions. J. Neurosci., 30, 3184-3198.